INT-787, a new name for TC-100 was recently announced by Intercept Therapeutics as their “next-generation” FXR agonist, primarily targeted at gut diseases and severe alcohol-associated hepatitis.614 Within an experiment in which HF diet ob/ob NASH model mice were given both INT-787 and OCA, only INT-787 lowered serum alanine transaminase, IL-1β, and TGFβ. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.